About
Cardiff Oncology is a clinical-stage company developing a highly selective, oral PLK1 inhibitor for the first-line treatment of patients with RAS-mutated metastatic colorectal cancer (mCRC), to improve outcomes for patients with these hard-to-treat tumors. Approximately half of patients with mCRC have tumors driven by mutations in a RAS gene1. These tumors are among the most treatment-resistant, and long-term survival with currently available therapies remains poor.
RAS-mutated colon cancer cells have shown increased dependence on PLK1 (polo-like kinase 1), a key regulator of cell division, for their proliferation and survival. Our approach targets PLK1 in combination with standard-of-care chemotherapy with the goal to enhance cancer cell death.
Our lead asset, onvansertib, is a highly selective, oral PLK1 inhibitor in development as a first-line treatment for KRAS- and NRAS-mutated mCRC in combination with FOLFIRI/bevacizumab (bev). In an ongoing randomized Phase 2 clinical trial, onvansertib + FOLFIRI/bev demonstrated dose-dependent improvements in overall response rate (72.2% ORR with 30 mg onvansertib + FOLFIRI/bev vs 42.1% with FOLFIRI/bev alone). Additionally, in contrast to the standard-of-care arms, median progression-free survival has not been reached in the 30 mg onvansertib + FOLFIRI/bev arm. Importantly, the combination of 30 mg onvansertib + FOLFIRI/bev demonstrates a favorable safety and tolerability profile.
Supported by clinical data and based on the serious unmet need, the U.S. Food and Drug Administration granted Fast Track designation to onvansertib + FOLFIRI/bev for the first-line treatment of adult patients with KRAS- or NRAS-mutated mCRC. Cardiff is advancing onvansertib toward a registrational trial in this setting.
Onvansertib is also being studied in investigator-initiated trials in chronic myelomonocytic leukemia (CMML) and other cancers and has received Orphan Drug Designations for CMML and small cell lung cancer.
1 American Cancer Society
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer, as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer and triple negative breast cancer. These programs and the broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone.
